Friedlander M - Search Results

1

"Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?

Davis A, Tinker AV, Friedlander M. Davis A, et al. Among authors: friedlander m. Gynecol Oncol. 2014 Jun;133(3):624-31. doi: 10.1016/j.ygyno.2014.02.038. Epub 2014 Mar 4. Gynecol Oncol. 2014. PMID: 24607285 Review.

2

Dual sequential non-cross-resistant chemotherapy for advanced stage squamous cell carcinoma of the cervix.

Levi JA, Wheeler HR, Friedlander M, Tattersall MH, Kefford R, Dalley D. Levi JA, et al. Among authors: friedlander m. Gynecol Oncol. 1992 Jun;45(3):329-33. doi: 10.1016/0090-8258(92)90314-9. Gynecol Oncol. 1992. PMID: 1377155

3

Risk factors, epidemiology, screening, and prognostic factors in female genital cancer.

Friedlander M, de Souza P, Segelov E. Friedlander M, et al. Curr Opin Oncol. 1992 Oct;4(5):913-22. doi: 10.1097/00001622-199210000-00016. Curr Opin Oncol. 1992. PMID: 1457507 Review.

4

Hypercalcemia in association with mucinous adenocarcinoma of the ovary: a case report.

Boyer M, Friedlander M, Bannatyne P, Atkinson K. Boyer M, et al. Among authors: friedlander m. Gynecol Oncol. 1989 Dec;35(3):387-90. doi: 10.1016/0090-8258(89)90085-1. Gynecol Oncol. 1989. PMID: 2557271

5

Cervical carcinoma: a drug-responsive tumor--experience with combined cisplatin, vinblastine, and bleomycin therapy.

Friedlander M, Kaye SB, Sullivan A, Atkinson K, Elliott P, Coppleson M, Houghton R, Solomon J, Green D, Russell P, et al. Friedlander M, et al. Gynecol Oncol. 1983 Oct;16(2):275-81. doi: 10.1016/0090-8258(83)90102-6. Gynecol Oncol. 1983. PMID: 6195052

6

High-dose chemotherapy in gynaecological cancers: does more mean better?

Links M, Friedlander M. Links M, et al. Among authors: friedlander m. Curr Opin Obstet Gynecol. 1995 Feb;7(1):49-52. Curr Opin Obstet Gynecol. 1995. PMID: 7742516 Review.

7

A phase II study of carboplatin and cisplatin in advanced ovarian cancer.

Segelov E, Stuart-Harris R, Bell D, Tattersall M, Hutton-Potts J, Friedlander M. Segelov E, et al. Among authors: friedlander m. Eur J Gynaecol Oncol. 1994;15(4):277-82. Eur J Gynaecol Oncol. 1994. PMID: 7957335 Clinical Trial.

8

Hypersensitivity reactions to etoposide. A report of three cases and review of the literature.

de Souza P, Friedlander M, Wilde C, Kirsten F, Ryan M. de Souza P, et al. Among authors: friedlander m. Am J Clin Oncol. 1994 Oct;17(5):387-9. Am J Clin Oncol. 1994. PMID: 8092107 Review.

9

Australasian multicentre phase II study of paclitaxel (Taxol) in relapsed ovarian cancer.

Phillips KA, Friedlander M, Olver I, Evans B, Smith J, Fitzharris B, McCrystal M, Joughin J, Bishop J. Phillips KA, et al. Among authors: friedlander m. Aust N Z J Med. 1995 Aug;25(4):337-43. doi: 10.1111/j.1445-5994.1995.tb01899.x. Aust N Z J Med. 1995. PMID: 8540875 Clinical Trial.

10

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.

Friedlander M, Millward MJ, Bell D, Bugat R, Harnett P, Moreno JA, Campbell L, Varette C, Ripoche V, Kayitalire L. Friedlander M, et al. Ann Oncol. 1998 Dec;9(12):1343-5. doi: 10.1023/a:1008469212268. Ann Oncol. 1998. PMID: 9932166 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results